'Grey's' Shonda Rhimes gets GLAAD award

Grey's Anatomy creator Shonda Rhimes. (UPI Photo/ Phil McCarten)

License photo

SAN FRANCISCO, June 3 (UPI) -- "Grey's Anatomy" creator Shonda Rhimes, was honored at the Gay and Lesbian Alliance Against Defamation Media Awards in San Francisco, the organization said.

GLAAD held the third installment of its 23rd annual Media Awards Saturday at the San Francisco Marriott Marquis, recognizing and honoring "media for their fair, accurate and inclusive representations of the LGBT community and the issues that affect their lives," the organization said in a news release.

Actors Kerry Washington, Guillermo Diaz and Katie Lowes presented Rhimes with the Golden Gate Award, which is given to an openly LGBT media professional who has made a significant difference in promoting equality.

"I think that love is universal. And I think in telling LGBT stories, I'm telling everyone's story. Love is, in fact, universal, right? I want my daughters to grow up in a world in which there is more love than hate," Rhimes said in her acceptance speech. "I'm going to do my best in the future to deserve the honor that's bestowed on me and make GLAAD proud."

Other award-winners included Wells Fargo for the Corporate Leader Award, Facebook for the Special Recognition Award, "Grey's Anatomy" for Outstanding Drama Series and "Days of Our Lives" for Outstanding Daily Drama, the release said. The award for Outstanding Digital Journalism Article went to Max J. Rosenthal of the Huntington Post for "Adam and Pete: Love in a Time of War."

Saturday's event in San Francisco wrapped up GLAAD's three-part Media Awards. Earlier ceremonies were held in New York City in March and Los Angeles in April.

More:
'Grey's' Shonda Rhimes gets GLAAD award

Chyler Leigh speaks out about her 'Grey's Anatomy' departure

After events in the show made it clear that Lexie Grey won't be returning for the 9th season of 'Grey's Anatomy,' Chyler Leigh talks about her departure from the show.

Two weeks after the deadly Greys Anatomy season finale, coupled with silence from Chyler Leigh, who played Lexie Grey, Leigh finally talks about her departure from the ABC show.

Lexie Grey was killed off in a fatal plane crash in the Season 8 finale of Greys Anatomy.

Earlier this year, I made the decision that season eight would be my last on Greys Anatomy. I met with Shonda and we worked together to give Lexies story appropriate closure, Leigh told TV Line.

Leigh was added to the cast during Season 4, after a brief appearance in the Season 3 finale. She was missing from the beginning of the eighth season after the shows creator, Shonda Rhimes, granted Leigh an extended hiatus from the show for family time.

Right after the finale, Rhimes took to Twitter to talk about Lexie Greys death.

I love Chyler and I love the character of Lexie Grey. She was an important member of my Grey's family. This was not an easy decision. But it was a decision that Chyler and I came to together. We had a lot of thoughtful discussion about it and ultimately we both decided this was the right time for her character's journey to end, Rhimes said.

Despite being killed off, Leigh is still appreciative of the show and her time on it, saying I am very lucky to have worked with this amazing cast and crew for five seasons. My experience on Greys Anatomy is something that I will treasure for the rest of my life. I want to take this time to say thank you to the fans. Your unconditional love and support have made these last five years very special for me. I look forward to my next chapter and I hope you will continue to follow me on my journey.

Along with Leigh, Kim Ravers Teddy Altman also left the show at the end of the season.

When talking about the upcoming season, Rhimes does not promise that everyone is safe. She tells TV Guide, Just because you saw people alive at the end of the finale doesn't mean they're going to be alive when the season starts up.

Original post:
Chyler Leigh speaks out about her 'Grey's Anatomy' departure

Chyler Leigh: I Chose to Leave Grey's Anatomy

Viewers may not have seen Lexie's grisly Grey's Anatomy death coming, but actress Chyler Leigh says her exit from the series was a while in the making.

In fact, once Leigh made the decision to part ways with the series, she was able to work with Grey's creator Shonda Rhimes to wrap up Lexie's five-and-a-half years on the show in a manner she deemed appropriate.

PHOTOS: TV bombshells

"Earlier this year, I made the decision that Season Eight would be my last on Grey's Anatomy. I met with Shonda and we worked together to give Lexie's story appropriate closure," Leigh, 30, tells TVLine.com in a new statement, two weeks after her character perished in a plane crash on the show's season finale.

PHOTOS: Grey's most memorable moments

Remaining tight-lipped on her future TV plans, Leigh expressed appreciation to the fans who supported her during her years on the ABC medical drama. "My experience on Grey's Anatomy is something that I will treasure for the rest of my life," her statement continued. "I want to take this time to say thank you to the fans. Your unconditional love and support have made these last five years very special for me. I look forward to my next chapter and I hope you will continue to follow me on my journey."

Fans weren't the only ones feeling the sting of Leigh's exit, which came at the same time Kim Raver's Teddy left Seattle Grace.

VIDEO: How the Grey's cast kills time on set

Rhimes explained via Twitter after the May 17 finale that killing off Lexie "was not an easy decision. But it was a decision that Chyler and I came to together. We had a lot of thoughtful discussion about it and ultimately we both decided this was the right time for her character's journey to end."

Tell Us: Do you feel better about Lexie's death knowing Chyler Leigh wanted to leave?

Link:
Chyler Leigh: I Chose to Leave Grey's Anatomy

Adamas Pharmaceuticals Presents Update On Nurelin™ Program At Cambridge Healthtech Institute's Parkinson's Conference

EMERYVILLE, Calif., June 4, 2012 /PRNewswire/ --Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its Nurelin (amantadine HCl extended release capsules) program at the Cambridge Healthtech Institute's (CHI) Targeting Parkinson's Disease Symposium being held today in Philadelphia. Nurelin, a once-daily extended release formulation of amantadine intended for night-time administration, is being developed for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) patients. Results from the Company's prior Phase 1 studies, its preclinical program in Parkinson's and other indications, along with a status report on the ongoing Phase 3 study, Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED), will be presented by Gregory T. Went, Ph.D., Co-Founder and Chief Executive Officer of Adamas. The talk is entitled, "Exploring the Potential of Modified Release Aminoadamantanes in Parkinson's Disease and Related Indications."

"We are excited to introduce the Nurelin program at the conference today, and to provide an update on the previous preclinical and clinical studies that have led to our first Phase 2/3 study of Nurelin in Parkinson's patients who experience levodopa-induced dyskinesia," said Dr. Went. "Amantadine is a remarkable drug that has received little attention from the pharmaceutical industry for the past 30 years, and we hope the EASED study of Nurelin, combined with recently presented academic studies in Parkinson's disease, will help establish new treatment indications for Nurelin. We look forward to presenting the results from this study and assessing the potential of Nurelin as our second NDA candidate to Arimenda."

There are no medications currently approved for the treatment of levodopa-induced dyskinesia, thus there is a significant unmet medical need. Pending the outcome of the EASED study and regulatory review, Nurelin may become the first drug indicated for the treatment of levodopa-induced dyskinesia in Parkinson's disease. Nurelin also is being investigated as a therapeutic agent to address the non-motor symptoms of Parkinson's disease, including fatigue.

About Nurelin (ADS-5102)

Nurelin (ADS-5102) is a proprietary formulation of amantadine in development for the treatment of central nervous system (CNS) disorders including LID in PD patients. Nurelin is designed for once daily administration at night and is being investigated at plasma concentrations up to 2.5 fold higher than those achievable with the commercially available immediate release amantadine tablets. Nurelin capsules can be opened and the contents sprinkled on food for ease of administration in patients who have difficulty swallowing capsules.

Nurelin has a pharmacokinetic profile designed to overcome the CNS side effects associated with immediate release forms of amantadine, while offering potential for enhanced efficacy. This novel pharmacokinetic profile of Nurelin is characterized by: i) higher plasma concentrations during the daytime hours when the motor and non-motor symptoms of Parkinson's disease are at their peak; ii) low plasma concentrations overnight, which may reduce sleep disturbance and vivid dreams occasionally associated with amantadine; and iii) a reduced initial rate of rise in plasma concentration, which is expected to improve overall CNS tolerability of amantadine.

The efficacy and tolerability of multiple doses of Nurelin in the treatment of LID in Parkinson's disease patients is currently being studied in a Phase 2/3 study. This study, entitled EASED (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia), is designed to evaluate the efficacy of three dose strengths of Nurelin for the treatment of LID, and to confirm the tolerability of the new formulation (www.easedPD.com).

About LID in Parkinson Disease

Parkinson's disease is a chronic, progressive disorder with prominent motor signs including tremors, rigidity, bradykinesia and postural instability. Levodopa, the most commonly prescribed and effective drug treatment for symptomatic relief in PD is associated with dose limiting motor side effects, including abnormal involuntary, dance-like movements known as dyskinesia. With continued levodopa treatment, and as PD progresses, dyskinesia can become severely disabling and has been associated with a decrease in the quality of life.

About Adamas

Go here to see the original:
Adamas Pharmaceuticals Presents Update On Nurelin™ Program At Cambridge Healthtech Institute's Parkinson's Conference

Adamas Pharmaceuticals Presents Update On Nurelin™ Program At Cambridge Healthtech Institute’s Parkinson’s Conference

EMERYVILLE, Calif., June 4, 2012 /PRNewswire/ --Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its Nurelin (amantadine HCl extended release capsules) program at the Cambridge Healthtech Institute's (CHI) Targeting Parkinson's Disease Symposium being held today in Philadelphia. Nurelin, a once-daily extended release formulation of amantadine intended for night-time administration, is being developed for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) patients. Results from the Company's prior Phase 1 studies, its preclinical program in Parkinson's and other indications, along with a status report on the ongoing Phase 3 study, Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED), will be presented by Gregory T. Went, Ph.D., Co-Founder and Chief Executive Officer of Adamas. The talk is entitled, "Exploring the Potential of Modified Release Aminoadamantanes in Parkinson's Disease and Related Indications."

"We are excited to introduce the Nurelin program at the conference today, and to provide an update on the previous preclinical and clinical studies that have led to our first Phase 2/3 study of Nurelin in Parkinson's patients who experience levodopa-induced dyskinesia," said Dr. Went. "Amantadine is a remarkable drug that has received little attention from the pharmaceutical industry for the past 30 years, and we hope the EASED study of Nurelin, combined with recently presented academic studies in Parkinson's disease, will help establish new treatment indications for Nurelin. We look forward to presenting the results from this study and assessing the potential of Nurelin as our second NDA candidate to Arimenda."

There are no medications currently approved for the treatment of levodopa-induced dyskinesia, thus there is a significant unmet medical need. Pending the outcome of the EASED study and regulatory review, Nurelin may become the first drug indicated for the treatment of levodopa-induced dyskinesia in Parkinson's disease. Nurelin also is being investigated as a therapeutic agent to address the non-motor symptoms of Parkinson's disease, including fatigue.

About Nurelin (ADS-5102)

Nurelin (ADS-5102) is a proprietary formulation of amantadine in development for the treatment of central nervous system (CNS) disorders including LID in PD patients. Nurelin is designed for once daily administration at night and is being investigated at plasma concentrations up to 2.5 fold higher than those achievable with the commercially available immediate release amantadine tablets. Nurelin capsules can be opened and the contents sprinkled on food for ease of administration in patients who have difficulty swallowing capsules.

Nurelin has a pharmacokinetic profile designed to overcome the CNS side effects associated with immediate release forms of amantadine, while offering potential for enhanced efficacy. This novel pharmacokinetic profile of Nurelin is characterized by: i) higher plasma concentrations during the daytime hours when the motor and non-motor symptoms of Parkinson's disease are at their peak; ii) low plasma concentrations overnight, which may reduce sleep disturbance and vivid dreams occasionally associated with amantadine; and iii) a reduced initial rate of rise in plasma concentration, which is expected to improve overall CNS tolerability of amantadine.

The efficacy and tolerability of multiple doses of Nurelin in the treatment of LID in Parkinson's disease patients is currently being studied in a Phase 2/3 study. This study, entitled EASED (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia), is designed to evaluate the efficacy of three dose strengths of Nurelin for the treatment of LID, and to confirm the tolerability of the new formulation (www.easedPD.com).

About LID in Parkinson Disease

Parkinson's disease is a chronic, progressive disorder with prominent motor signs including tremors, rigidity, bradykinesia and postural instability. Levodopa, the most commonly prescribed and effective drug treatment for symptomatic relief in PD is associated with dose limiting motor side effects, including abnormal involuntary, dance-like movements known as dyskinesia. With continued levodopa treatment, and as PD progresses, dyskinesia can become severely disabling and has been associated with a decrease in the quality of life.

About Adamas

Go here to see the original:
Adamas Pharmaceuticals Presents Update On Nurelin™ Program At Cambridge Healthtech Institute's Parkinson's Conference

Researchers ID Cluster of Genes in Blood that Predict Parkinson’s

Newswise Because there is currently no laboratory test that can diagnose Parkinsons disease, it is practically impossible to detect those individuals who are in the earliest stages of the disease. As a result, Parkinsons disease can only be diagnosed by a clinical neurological examination based on findings suggestive of the disease.

But researchers from the Technion-Israel Institute of Technology Faculty of Medicine have now identified a biomarker comprised of five genes shown to predict Parkinson's disease with high accuracy. The findings are reported in a research article now published online by the scientific journal Molecular Neurodegeneration.

A predictive biomarker for Parkinson's disease could also help to identify high-risk individuals before symptoms develop a stage where prevention treatment efforts might be expected to have their greatest impact to slow disease progression, says lead researcher Dr. Silvia Mandel. It could allow diagnosis of carriers of the genetic risk factors, or those who may exhibit pre-symptomatic stages of the disease [depression, sleep disturbances or hyposmia (reduced ability to smell)] and are good candidates for neuroprotective treatment.

All five genes that comprise the biomarker play a role in the ubiquitin-proteasome system of protein degradation, whose involvement in the pathology of Parkinson's disease has previously been demonstrated.

The study was conducted on blood samples from 62 early stage Parkinson's disease patients and 64 healthy age-matched control subjects. The selection of the genes and determination of their expression in the blood was based on previous research conducted by Dr. Mandel and Prof. Moussa Youdim on the brains of deceased Parkinson's disease patients.

More strikingly, in 30 patients at advanced stages of Parkinson's disease, the model was 100 percent accurate. It was also able to fully discriminate between Parkinson's disease and Alzheimer's disease.

The researchers believe the blood test could one day be combined with brain imaging and/or biomarkers in the spinal fluid or other peripheral tissues, as a gold standard not only for early diagnosis, but also for the differential diagnosis of Parkinson's disease and motor disorders that often mimick the disease symptoms.

Dr. Mandel, who is Vice Director of the Eve Topf Center of Excellence for Neurodegenerative Diseases Research and Teaching at the Technion, conducted the research together with her PhD student Leonid Molochnikov, Professor Youdim; Prof. Judith Aharon of Rambam Medical Center; and Prof. Martin Rabey of Assaf HaRofeh Medical Center. Scientists from the Universities of Wrzburg and Pisa also contributed to the research.

The Technion-Israel Institute of Technology is consistently ranked among the world's leading science and technology universities. Home to three of Israel's five winners of the Nobel Prize in science, the Technion commands a worldwide reputation for its pioneering work in computer science, nanotechnology, biotechnology, energy, water-resource management, medicine, drug development, and aerospace. Headquartered in New York City, the American Technion Society (ATS) promotes scientific and technological research and education at the Technion.

Read the original here:
Researchers ID Cluster of Genes in Blood that Predict Parkinson's

Researchers ID Cluster of Genes in Blood that Predict Parkinson's

Newswise Because there is currently no laboratory test that can diagnose Parkinsons disease, it is practically impossible to detect those individuals who are in the earliest stages of the disease. As a result, Parkinsons disease can only be diagnosed by a clinical neurological examination based on findings suggestive of the disease.

But researchers from the Technion-Israel Institute of Technology Faculty of Medicine have now identified a biomarker comprised of five genes shown to predict Parkinson's disease with high accuracy. The findings are reported in a research article now published online by the scientific journal Molecular Neurodegeneration.

A predictive biomarker for Parkinson's disease could also help to identify high-risk individuals before symptoms develop a stage where prevention treatment efforts might be expected to have their greatest impact to slow disease progression, says lead researcher Dr. Silvia Mandel. It could allow diagnosis of carriers of the genetic risk factors, or those who may exhibit pre-symptomatic stages of the disease [depression, sleep disturbances or hyposmia (reduced ability to smell)] and are good candidates for neuroprotective treatment.

All five genes that comprise the biomarker play a role in the ubiquitin-proteasome system of protein degradation, whose involvement in the pathology of Parkinson's disease has previously been demonstrated.

The study was conducted on blood samples from 62 early stage Parkinson's disease patients and 64 healthy age-matched control subjects. The selection of the genes and determination of their expression in the blood was based on previous research conducted by Dr. Mandel and Prof. Moussa Youdim on the brains of deceased Parkinson's disease patients.

More strikingly, in 30 patients at advanced stages of Parkinson's disease, the model was 100 percent accurate. It was also able to fully discriminate between Parkinson's disease and Alzheimer's disease.

The researchers believe the blood test could one day be combined with brain imaging and/or biomarkers in the spinal fluid or other peripheral tissues, as a gold standard not only for early diagnosis, but also for the differential diagnosis of Parkinson's disease and motor disorders that often mimick the disease symptoms.

Dr. Mandel, who is Vice Director of the Eve Topf Center of Excellence for Neurodegenerative Diseases Research and Teaching at the Technion, conducted the research together with her PhD student Leonid Molochnikov, Professor Youdim; Prof. Judith Aharon of Rambam Medical Center; and Prof. Martin Rabey of Assaf HaRofeh Medical Center. Scientists from the Universities of Wrzburg and Pisa also contributed to the research.

The Technion-Israel Institute of Technology is consistently ranked among the world's leading science and technology universities. Home to three of Israel's five winners of the Nobel Prize in science, the Technion commands a worldwide reputation for its pioneering work in computer science, nanotechnology, biotechnology, energy, water-resource management, medicine, drug development, and aerospace. Headquartered in New York City, the American Technion Society (ATS) promotes scientific and technological research and education at the Technion.

Read the original here:
Researchers ID Cluster of Genes in Blood that Predict Parkinson's

New research yields insights into Parkinson's disease

Public release date: 4-Jun-2012 [ | E-mail | Share ]

Contact: Kagan Kerman kkerman@utsc.utoronto.ca 416-287-7249 University of Toronto Scarborough

Researchers at the University of Toronto Scarborough (UTSC) used an innovative technique to examine chemical interactions that are implicated in Parkinson's Disease.

The work details how a protein called alpha-synuclein interacting with the brain chemical dopamine can lead to protein misfolding and neuronal death.

Parkinson's Disease is a neurodegenerative disease which results in loss of motor control and cognitive function. Although the cause isn't known precisely, the disease involves the death of brain cells that produce dopamine, a chemical important in neuronal signaling. The disease also involves a protein called alpha-synuclein which aggregates in the neurons of people with the disease.

Kagan Kerman, a chemist in the Department of Physical and Environmental Sciences, and Ian R. Brown, a neuroscientist who founded UTSC's Centre for the Neurobiology of Stress in the Department of Biological Sciences, looked at the way dopamine interacts with alpha-synuclein to form aggregates that may be toxic to neurons.

"This is very fundamental," says Kagan Kerman. "It gives us a new point of view of the misfolding proteins and how they are affected by dopamine."

These sorts of interactions are often studied using microscopy. But the UTSC researchers decided to use an electroanalytic technique called voltammetry. By studying tiny changes in electric current as dopamine and alpha-synuclein interacted they were able to determine details about the early phases of the interaction.

Using the technique, they were able to detail how changes in pH levels and ionic strength of the solution affected the interaction. They found that at higher pH levels and higher ionic strengths, dopamine interacted much more strongly with alpha-synuclein, forming aggregates more quickly.

The results could have implications for understanding and treating the disease. Normally dopamine is contained in structures called vesicles, in which pH levels are low and dopamine is unlikely to interact with alpha-synuclein. Outside of the vesicles dopamine encounters higher pH levels and, according to the new research, is much more likely to interact to create aggregates.

Go here to read the rest:
New research yields insights into Parkinson's disease

New research yields insights into Parkinson’s disease

Public release date: 4-Jun-2012 [ | E-mail | Share ]

Contact: Kagan Kerman kkerman@utsc.utoronto.ca 416-287-7249 University of Toronto Scarborough

Researchers at the University of Toronto Scarborough (UTSC) used an innovative technique to examine chemical interactions that are implicated in Parkinson's Disease.

The work details how a protein called alpha-synuclein interacting with the brain chemical dopamine can lead to protein misfolding and neuronal death.

Parkinson's Disease is a neurodegenerative disease which results in loss of motor control and cognitive function. Although the cause isn't known precisely, the disease involves the death of brain cells that produce dopamine, a chemical important in neuronal signaling. The disease also involves a protein called alpha-synuclein which aggregates in the neurons of people with the disease.

Kagan Kerman, a chemist in the Department of Physical and Environmental Sciences, and Ian R. Brown, a neuroscientist who founded UTSC's Centre for the Neurobiology of Stress in the Department of Biological Sciences, looked at the way dopamine interacts with alpha-synuclein to form aggregates that may be toxic to neurons.

"This is very fundamental," says Kagan Kerman. "It gives us a new point of view of the misfolding proteins and how they are affected by dopamine."

These sorts of interactions are often studied using microscopy. But the UTSC researchers decided to use an electroanalytic technique called voltammetry. By studying tiny changes in electric current as dopamine and alpha-synuclein interacted they were able to determine details about the early phases of the interaction.

Using the technique, they were able to detail how changes in pH levels and ionic strength of the solution affected the interaction. They found that at higher pH levels and higher ionic strengths, dopamine interacted much more strongly with alpha-synuclein, forming aggregates more quickly.

The results could have implications for understanding and treating the disease. Normally dopamine is contained in structures called vesicles, in which pH levels are low and dopamine is unlikely to interact with alpha-synuclein. Outside of the vesicles dopamine encounters higher pH levels and, according to the new research, is much more likely to interact to create aggregates.

Go here to read the rest:
New research yields insights into Parkinson's disease

Horses as a Treatment for Multiple Sclerosis

I've always loved horses. I've been riding since I was five, I come from a horse family, says Patricia Labau of Gunnison, CO. Her life revolved around horses. She was competing, showing and jumping... Until one day when her life suddenly changed.

I woke up one morning and couldn't walk, she says.

She learned some news she never expected.

They diagnosed me with multiple sclerosis, she explains.

Multiple sclerosis is a debilitating disease. But Labau didnt let it keep her from the stables.

Sometimes you can get sick and go, ugh, and I'm not one of those people. I went ok, how can we fix this?

She used a form of riding called dressage as her therapy.

Dressage is to riding as ballet is to dance. Its a classical, very logical systematic approach, says Alice West, announcer and trainer for Grand Valley Dressage Show.

Dressage is a slower form of riding that takes incredible muscle control from the rider.

It also involves very intense training on the part of the rider. The rider has to have a very supple and elastic seat so they don't interfere with the horses motion and yet still be able to influence the horse, West says.

Here is the original post:
Horses as a Treatment for Multiple Sclerosis

Agencies demand curbs on drugs for dementia

June 04--Many institutionalized dementia patients are known to lash out as part of their condition -- to strike the aides trying to feed or clean them, to yell at other patients, to aggressively resist intrusive but necessary medical care such as IVs and catheters.

They are also known to be heavily medicated to control such behavior, a practice that government officials, nursing home industry leaders and patient care advocates say needs to be curbed.

The federal Centers for Medicare & Medicaid Services, or CMS, and the others announced an initiative last week designed to reduce use of antipsychotic drugs on nursing home patients with dementia by 15 percent by year's end. Too often, they say, the staffs of long-term care facilities have relied on the medications to control behavior of patients with Alzheimer's or a similar disease instead of trying other methods, even though the health of those residents can be damaged.

"It's often related to care activities in which the [patient] becomes frightened, bewildered, apprehensive, very anxious -- they don't know what's happening and may resist care or may actually strike out," said Jules Rosen, chief of geriatric psychiatry at UPMC. "What has happened culturally is the knee-jerk reaction of many staff and many doctors is to prescribe these drugs, that it will calm them down. It serves that purpose for some people, and doesn't for others."

The two leading trade groups representing nursing homes, the American Health Care Association and LeadingAge, endorsed the CMS initiative and said they would work with the government to help steer facilities toward other methods with difficult patients. By July, the federal agency plans to list on its website devoted to nursing home comparisons the statistics describing each facility's use of antipsychotic medications on dementia patients.

"We're seeing a number of facilities steer away from these medications, but it's still way too high," said David Gifford, the AHCA's senior vice president of quality and regulatory affairs. "One of the biggest challenges is many clinicians, physicians, nurses and family members think these medications are necessary and effective, but data suggest otherwise."

A CMS report on the issue found that nearly 40 percent of nursing patients with signs of dementia in 2010 received antipsychotic drugs when they did not have any of the conditions for which the medications were government-approved, such as schizophrenia or bipolar disorder. It also stated more than 17 percent of nursing home residents had daily doses of the drugs exceeding recommended levels.

The new initiative calls upon nursing homes to assign consistent staff that gets to know the patients better and can more reliably understand their needs, considering the difficulty many dementia patients have in expressing themselves. Facilities are also being urged to devote more time to alternative behavioral solutions such as music therapy, exercise and other social activities.

Claire Curry, a legal director for the Legal Aid Justice Center, which advocates for patients, said the nursing homes need to learn "to not reach for a magic pill that's going to tranquilize someone, but use these other tools I'm so happy to see CMS pushing. The drug should always be a very last resort."

Government and medical officials note that while commonly used antipsychotic medications such as risperidone and olanzapine can be beneficial, they have not been proved to have the same value for dementia patients as for their intended use and there can be more harmful side effects for patients with Alzheimer's or similar conditions.

More:
Agencies demand curbs on drugs for dementia

PRICETON: Steve Carell addresses class of 2012

Despite pouring rain Monday morning, throngs of Princeton University graduates gathered on Cannon Green for their Class Day ceremonies, where a local teen was made an honorary class member and actor Steve Carell addressed the students.

Derek DiGregorio, 14, of Princeton, received the loud cheers as he was inducted as an honorary member of the class.

Derek has touched the hearts of many throughout the Princeton community and the Class of 2012, said John Monagle, class treasurer, as he introduced the boy during the ceremony. Hes had a deep impact on many of our classmates Princeton experiences.

Derek, an eighth grader at John Witherspoon Middle School, was born 14 years ago with a disease called ataxia telagiectasia (A-T) that will eventually rob him of movement, compromise his immune system and may cause cancer.

Derek has worked to raise awareness of A-T and to support families who are also facing the disease, said Mr. Monagle, who noted to loud cheers, that the boy is a five-time world champion in tae kwon do and a gold medalist in bowling at the New Jersey Special Olympics. Dereks story is one of courage, passion and determination. He lives the values Princetonians hope to embody and Im honored to present Derek as an honorary class member of the Class of 2012.

According to Derek, the honor was awesome, and he plans to wear his class jacket to school on June 5.

It felt really, really good and it was very special to be a part of something like that, said Derek after returning home from the ceremony and lunch party on campus.

Dereks father, Steve DiGregorio, is a former Princeton University football coach from 1987 to 1999 who left the team to spend more time with his son.

I dont have words; this is so overwhelming for all of us, said Mr. DiGregorio. We got word two and a half, three weeks ago that this was going on, and we are so overwhelmed. My wife and I are very grateful for all of this and very grateful to the senior class for doing this for Derek and making it such a special day for our family.

See the article here:
PRICETON: Steve Carell addresses class of 2012

The Classic notebook: Veteran runner Baker still cooking at 50

Buy This Photo

Frank Shorter, left, autographs White Plains runner Alicia Sokolofsky's bib on Sunday.JEFF GOULDING/Times Herald-Record

Published: 2:00 AM - 06/04/12

MIDDLETOWN Brian Baker doesn't seem to age, from his youthful appearance to his spectacularly consistent road running times.

Baker, of Walden, turned 50 this year, but continues to clock times that would make a 20-year-old proud. He won the 50- to 54-year-old age group in 39:54 on Sunday at The Classic 10K.

Baker is within only 90 seconds or so of times he ran as a 19-year-old. He has missed only four of the 32 Classics (2006-present) and Orange Classics (1981-2005).

"I'm psyched that I'm maintaining that consistency,'' he said.

A vegetarian most of his life, Baker chalks up his remarkable consistency to "good genes and a healthy lifestyle.'' He's also durable, having run for 36 years without being slowed by any chronic injuries. Baker finished his 37th marathon at Boston in April.

Liberty High graduate Mike Belfiore raised more than $5,000 on Sunday for Juvenile Diabetes, honoring a friend's daughter recently diagnosed with the disease at 18 months old.

"It broke my heart to see them go through what they went through,'' said Belfiore, a father of children ages 5 and 1. He said his friend's daughter is doing well. Belfiore set a goal of $5,000 and had raised about $5,400 through Sunday. Donations to the cause in Belfiore's name can be made at jdrf.org.

Read this article:
The Classic notebook: Veteran runner Baker still cooking at 50

Antioxidant May Reduce Irritability In Kids With Autism

Editor's Choice Main Category: Autism Also Included In: Pediatrics / Children's Health;Psychology / Psychiatry Article Date: 04 Jun 2012 - 10:00 PDT

Current ratings for: 'Antioxidant May Reduce Irritability In Kids With Autism'

4 (1 votes)

5 (1 votes)

The pilot trial, conducted by researchers at Stanford University School of Medicine and Lucile Packard Children's Hospital, involved 31 children aged 3 to 12 years with autism. The study is published in Biological Psychiatry.

The researchers found that NAC reduced irritability and repetitive behaviors of the children. However, before NAC can be recommended for children with autism, larger trials are needed in order to verify results from the pilot trial.

Between 60-70% of children with the disorder suffer from irritability. Antonio Hardan, M.D., an associate professor of psychiatry and behavioral sciences at Stanford and director of the Autism and Developmental Disabilities Clinic at Packard Children's explained:

One of the top priorities for researchers is to find new medications to treat autism and its symptoms. At present, aggression, irritability, and mood swings are all associated features of the disorder and are treated with second-generation antipsychotics.

However, these medications cause serious adverse effects including:

Another major problem of autism is the state of drug treatments for its core features, such as repetitive behaviors, social deficits, and language impairment. Hardan said: "Today, in 2012, we have no effective medication to treat repetitive behavior such as hand flapping or any other core features of autism."

See the original post here:
Antioxidant May Reduce Irritability In Kids With Autism

What’s Different About The Brains Of People With Autism?

Enlarge Rebecca Droke/Pittsburgh Post-Gazette

Jeff Hudale, who is autistic, demonstrates a face recognition test at the University of Pittsburgh in 2010. Researchers use eye tracking devices to monitor and record what he is looking at.

Jeff Hudale, who is autistic, demonstrates a face recognition test at the University of Pittsburgh in 2010. Researchers use eye tracking devices to monitor and record what he is looking at.

Like a lot of people with autism, Jeff Hudale has a brain that's really good at some things.

"I have an unusual aptitude for numbers, namely math computations," he says.

Hudale can do triple-digit multiplication in his head. That sort of ability helped him get a degree in engineering at the University of Pittsburgh. But he says his brain struggles with other subjects like literature and philosophy.

"I like working with things that are rather concrete and structured," he says. "Yeah, I like things with some logic and some rules to it."

So Hudale, who is 40, does fine at his job at a bank. But he doesn't do so well with social interactions, where logic and rules aren't so obvious.

"Most people my age are nowadays married," he says. "But me, not only am I totally single, I've never even had a date."

What Hudale has done for the past 25 years is help scientists understand autism by letting them study his brain.

Read the rest here:
What's Different About The Brains Of People With Autism?

What's Different About The Brains Of People With Autism?

Enlarge Rebecca Droke/Pittsburgh Post-Gazette

Jeff Hudale, who is autistic, demonstrates a face recognition test at the University of Pittsburgh in 2010. Researchers use eye tracking devices to monitor and record what he is looking at.

Jeff Hudale, who is autistic, demonstrates a face recognition test at the University of Pittsburgh in 2010. Researchers use eye tracking devices to monitor and record what he is looking at.

Like a lot of people with autism, Jeff Hudale has a brain that's really good at some things.

"I have an unusual aptitude for numbers, namely math computations," he says.

Hudale can do triple-digit multiplication in his head. That sort of ability helped him get a degree in engineering at the University of Pittsburgh. But he says his brain struggles with other subjects like literature and philosophy.

"I like working with things that are rather concrete and structured," he says. "Yeah, I like things with some logic and some rules to it."

So Hudale, who is 40, does fine at his job at a bank. But he doesn't do so well with social interactions, where logic and rules aren't so obvious.

"Most people my age are nowadays married," he says. "But me, not only am I totally single, I've never even had a date."

What Hudale has done for the past 25 years is help scientists understand autism by letting them study his brain.

Read the rest here:
What's Different About The Brains Of People With Autism?

Foods for children with autism

As a certified holistic health counselor and a mother, Ive had my share of experience helping children with disabilities. Over the next three weeks, I will be featuring three disabilities that are increasingly prevalent: Autism spectrum disorder (ASD), Down syndrome and cerebral palsy.

Dr. Manny Alvarez, senior managing health editor at FoxNews.com, has asked that I offer suggestions on diets to support children with these special needs. We will be taking a look at brain physiology, common physical symptoms, nourishing foods and foods to avoid.

First up this week is ASD. The most recent statistics indicate approximately 1 in 88 children in the U.S are on the spectrum.

Autistic manifestations usually begin to appear between the first and second year of life and include delays or abnormalities in language and complex behavior, social interactions, repetitive behavior or unusual interests and preoccupations. According to The Autism Society there is no single cause of autism and most cases involve a combination of genetic risk factors, environmental factors and very early brain development.

Studies published by Autism Speaks show that a set of biochemical pathways (methylation, transsulfration and sulfation) tend to function sub-optimally for those with autism. These pathways are involved in detoxification, heavy metal elimination, digestion, immune function and gut integrity.

Gastrointestinal symptoms and inflammation are very common for those on the spectrum. These include diarrhea, constipation, bloating and GI pain.

Gut inflammation is typically caused by food sensitivities and an overabundance of unhealthy bacteria in the gut. Impaired digestion causes nutrient deficiencies and impaired cellular function, which manifests as poor brain function and immune system deficiencies. When food is not broken down properly, as is the case with food sensitivities, it leads to foggy thinking, insensitivity to pain, withdrawal and irritability.

The most common culprits of food sensitivities are gluten, casein and soy. Other common physical symptoms are frequent infections, trouble sleeping, non-localized pain/inflammation and brain fog. These symptoms are typical of yeast overgrowth and excessive toxins.

There is a clear connection between the brain and the gut. Supporting the physical symptoms through diet will increase overall health and should reduce the severity of symptoms.

In order to heal the gut, it is important to eat a diet rich in foods with anti-inflammatory properties such as omega-3 fatty acids found in fish oil (fatty fish such as salmon and sardines), flax seeds and walnuts to reduce any existing gut inflammation.

Continue reading here:
Foods for children with autism

The Case for Autism Coverage

With autism affecting one in 88 children, companies and lawmakers are stepping up efforts to see that treatments are covered by health benefits.

By JONATHAN BERR, who has written for national media outlets for more than 15 years.

Employees at The Autism Society, a small non-profit dedicated to raising public awareness about the condition, are offered a wide array of benefits -- except, ironically coverage for autism.

"It's amazing," said Scott Badesch, the society's president and COO, who is lobbying state officials to change the law.

Maryland is behind the times. One in 88 children suffer from autism. Around 30 states have passed laws requiring companies to offer coverage for autism and services such as speech, occupational and behavioral therapies. These laws don't apply in general to large companies whose health insurance plans are self-funded. But even in those cases, there is progress as more of them are helping to cover the costs of these treatments.

"I am pleasantly surprised at the rapid growth of the number of companies that are offering autism benefits," said Lori Unub, vice president for state government affairs at Autism Speaks, adding that a German firm was basing its decision on where to locate its U.S. operations on whether a particular state required autism insurance coverage. "I actually cannot keep up with all the emails that I get. ?It is still the tip of the iceberg."

IBM, Capital One and Ohio State University are among employers that assist workers in paying for scientifically recognized autism treatments and therapies. IBM, the world's largest provider of computer services, offers a program to cover costs outside the scope of the company's health insurance plan. It has a lifetime maximum benefit of $50,000, according to the Armonk, N.Y.-based company. In addition, IBM provides LifeWorks, which offers around-the-clock personal phone support from trained disability consultants.

Capital One, the sixth-largest U.S. commercial lender by deposits, offers autism benefits because the company believes that it's the right thing to do, said Eric Gutierrez, vice president of HR benefits.

The McLean, Va.-based company offers coverage for applied behavioral analysis -- a common autism treatment that has been shown to be effective -- along with speech, occupational and physical therapy. It also funds and supports a program for autistic adults so they can experience what it's like to work in a Fortune 500 company.

"These types of benefits are definitely having a positive impact on hiring and retention," Guitierrez said. "We have several stories of associates whose decision to join our company were influenced by our great benefits, including the autism benefits. This is a tremendous retention tool for the associates using these benefits, as most would not be able to afford these services on their own. Many associates, even those without children with autism, have told us that the autism program speaks volumes for our values as an organization."

Read more:
The Case for Autism Coverage

NASCAR revs up autism-friendly event

Yet families affected by autism are still often left feeling like they are not truly part of their communities. Some of that feeling of isolation comes from the fact that it can be challenging if not outright impossible for families like mine to take part in activities that most take for granted. Whether its going to a movie, heading out for a pancake breakfast, catching a baseball game, or attending a town barbecue, we often decide its ultimately not worth taking the risk that what should be a fun outing could turn into a fiasco.

Fortunately, there is a growing movement to develop events or modify existing ones that take the unique needs of people with autism into consideration and create marvelous experiences for them. Broadway theaters have started hosting special performances for families with autism, featuring toned-down lighting, sound, and special effects, as well as quiet rooms for kids who need some time away from the action. Movie theater chains host autism-only screenings, where parents dont have to worry if their child screams or otherwise acts out.

I am proud to be involved with a new effort that will hopefully inspire others to follow suit. Dover International Speedway, NASCAR, FedEx, and the national advocacy organization Autism Speaks are partnering to create the first autism-friendly NASCAR race experience for families. At this weekends FedEx 400, families with autism can attend the "Autism Speaks Day at the Races," which will feature prerace presentations on the latest autism research and services available to families. During the race, a "quiet zone" in the grandstand will allow parents to bring their kids to a sensory-friendly place to take in the action away from the crowd and noise.

Not every entertainment venue can accommodate families in this way, but it is important for organizations such as NASCAR, movie theater chains, restaurants, and others to know that doing so isnt just a good deed its also good business. Like all families, we "vote" with our wallets, spending our limited entertainment dollars where they will bring us the best experiences. Autism-friendly events are business-savvy, and they help develop communities that are inclusive and welcoming for all.

Continued here:
NASCAR revs up autism-friendly event